Literature DB >> 9143707

Gp130 and the interleukin-6 family of cytokines.

T Taga1, T Kishimoto.   

Abstract

Receptors for most interleukins and cytokines that regulate immune and hematopoietic systems belong to the class I cytokine receptor family. These molecules form multichain receptor complexes in order to exhibit high-affinity binding to, and mediate biological functions of, their respective cytokines. In most cases, these functional receptor complexes share common signal transducing receptor components that are also in the class I cytokine receptor family, i.e. gp130, common beta, and common gamma molecules. Interleukin-6 and related cytokines, interleukin-11, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, and cardiotrophin-1 are all pleiotropic and exhibit overlapping biological functions. Functional receptor complexes for this interleukin-6 family of cytokines share gp130 as a component critical for signal transduction. Unlike cytokines sharing common beta and common gamma chains that mainly function in hematopoietic and lymphoid cell systems, the interleukin-6 family of cytokines function extensively outside these systems as well, e.g. from the cardiovascular to the nervous system, owing to ubiquitously expressed gp130. Stimulation of cells with the interleukin-6 family of cytokines triggers homo- or hetero-dimerization of gp130. Although gp130 and its dimer partners possess no intrinsic tyrosine kinase domain, the dimerization of gp130 leads to activation of associated cytoplasmic tyrosine kinases and subsequent modification of transcription factors. This paper reviews recent progress in the study of the interleukin-6 family of cytokines and gp130.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143707     DOI: 10.1146/annurev.immunol.15.1.797

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  380 in total

Review 1.  New insights into the biology of the acute phase response.

Authors:  A F Suffredini; G Fantuzzi; R Badolato; J J Oppenheim; N P O'Grady
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

Review 2.  Receptor recognition by gp130 cytokines.

Authors:  J Bravo; J K Heath
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

Review 3.  Interleukin 6 and liver regeneration.

Authors:  K L Streetz; T Luedde; M P Manns; C Trautwein
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

4.  Cytokine-responsive induction of SAF-1 activity is mediated by a mitogen-activated protein kinase signaling pathway.

Authors:  Alpana Ray; Guang-Yao Yu; Bimal K Ray
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

Review 5.  Cytokines: past, present, and future.

Authors:  J J Oppenheim
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

6.  K-Ras mediates cytokine-induced formation of E-cadherin-based adherens junctions during liver development.

Authors:  Takaaki Matsui; Taisei Kinoshita; Yoshihiro Morikawa; Kazuo Tohya; Motoya Katsuki; Yoshiaki Ito; Akihide Kamiya; Atsushi Miyajima
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

Review 7.  What does Stat3 do?

Authors:  David E Levy; Chien-kuo Lee
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 8.  Role of the JAK/STAT signal transduction pathway in the regulation of gene expression in CNS.

Authors:  P Dell'Albani; R Santangelo; L Torrisi; V G Nicoletti; A M Giuffrida Stella
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

9.  A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3.

Authors:  Koh Nakayama; Kyung-Woon Kim; Atsushi Miyajima
Journal:  EMBO J       Date:  2002-11-15       Impact factor: 11.598

10.  Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.

Authors:  Weirong Wang; Xiaofeng Wang; Rajitha Doddareddy; Damien Fink; Thomas McIntosh; Hugh M Davis; Honghui Zhou
Journal:  AAPS J       Date:  2013-11-28       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.